Latest Non Dilutive Funding News

Metallium Limited has kicked off commissioning at its Texas Technology Campus, sealed a multi-year feedstock deal with Glencore, and bolstered its balance sheet with a A$75 million capital raise, setting the stage for commercialisation in 2026.

GoldArc Resources has identified multiple high-priority gold targets at its Leonora projects and secured strategic partnerships to accelerate mining development, backed by a $2.5 million cash advance facility.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Cosmo Metals has identified two promising volcanic massive sulphide targets within the Mt Everest – Mona corridor at its Bingara Project, setting the stage for the first drilling campaign in this historically underexplored VMS belt.

EMVision Medical Devices reports strong clinical trial progress for its portable brain scanners, backed by solid cash reserves and milestone grant funding.

Heavy Minerals Limited has formalised a binding agreement with Hillgrove Resources to develop a pioneering garnet extraction project at the Kanmantoo Copper Mine, aiming to start production in late 2026.

Actinogen Medical has locked in a $4.3 million tranche of non-dilutive funding to support its pivotal Alzheimer’s disease trial, reinforcing its financial position as it nears critical interim and final results.

Nova Minerals has secured US$43.4 million in non-dilutive funding from the U.S. Department of War to fully fund its domestic antimony supply chain development in Alaska, while also progressing its vast Estelle gold project with promising drilling results.

Island Pharmaceuticals has secured key regulatory milestones for its antiviral Galidesivir, including FDA confirmation of the Animal Rule pathway and Priority Review Voucher eligibility, while strengthening US biodefense ties and expanding patent protection.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.